We are proud to share the reports published by Public Health England who have demonstrated successful inactivation of SARS-CoV-2 using our 3 virusPHIX™ products: virusPHIX+™ Our original formulation, developed for PCR testing on swab and saliva samples PHE Inactivation study Triplicate samples of tissue culture fluid containing 5% (v/v) foetal calf serum, spiked with SARS-CoV-2 [...]
We would like to wish all our customers a very merry Christmas and a happy new year. Please note that our offices close on Thursday 24th December and will reopen on Monday 4th January. After what has been a tough year for everyone, we look forward to a bright and healthy 2021.
Rapid Labs have been awarded an £80,000 grant from Tendring District Council to increase production capacity at their biomedical facility in Little Bentley. The grant has contributed towards the cost of a new ISO 8 clean room facility, which is primarily being used for the manufacture and development of a novel RNA stabiliser and virus [...]
We are pleased to announce that Rapid Labs Ltd have been awarded membership of the British In Vitro Diagnostics Association (BIVDA). BIVDA is the national industry association for the manufacturers and distributors of IVD products in the UK and currently represent more than 95% of the industry and over a hundred organisations ranging from British [...]
The Pasteur Institute has successfully demonstrated inactivation of the Zika Virus using vivoPHIX™: To determine the ability of vivoPHIX™ to inhibit ZIKV in mosquito tissue sample, ZIKV-infected mosquito midguts were dissected at 6 dpi. Mosquito midguts were then chopped into 3-4 small pieces then transfer into vivoPHIX™. Samples were then treated at 4 degree Celsius [...]
Following last week's announcement regarding the development of our new reagent, virusPHIX™ and call for trial sites to evaluate it's suitability for COVID-19 testing, we are pleased to share our new product brochure. The virusPHIX™ brochure includes information about its key features, list of viruses it has successfully inactivated, preliminary data regarding inactivation of SARS-CoV-2 [...]
May 2020 Press Release Rapid Labs Ltd (Essex, UK), RNAssist (Cambridge, UK) and Qnostics (Glasgow, UK) are currently developing and seeking trial sites to validate the virusPHIX™ RNA stabilisation, cell fixative and virus inactivation reagent for SARS-CoV-2 testing on nasopharangeal swab samples and saliva/sputum samples. Offer; A universal sample collection tube for liquid samples including; [...]
Dear customers, As you are aware, the coronavirus pandemic is continuing to cause major disruptions across the globe. Rapid Labs are proud to be part of the medical diagnostics industry, and we will continue to remain open, offering hundreds of diagnostic tests to hospitals around the world until any closures are forced upon us by [...]
We are proud to be the international distributor for NHSBT Cell Screening Panels for use in transfusion medicine, criminology and paternity testing outside the UK. All reagents are CE-marked and comply with the standards laid down in the Guidelines for Blood Transfusion Services in the UK (Current-edition). They are prepared to be the best standards [...]
RNAssist and Rapid Labs Agree on Manufacturing and Supply Agreement for genoPHIX™ and vivoPHIX™ Biomolecule Stabilisation, Tissue Fixation and Microbial Inactivation Technology. Cambridge and Colchester, UK. 22nd January 2020 RNAssist (www.RNAssist.com) has developed several universal biological sample stabilisation, fixation and microbial inactivation reagents. Rapid Labs (www.rapidlabs.co.uk) a manufacturer and supplier of medical and veterinary diagnostic reagents, announced [...]